Agency
Children's Hospital Colorado
Children's Hospital Colorado was paid $114.90M by Medicaid between Jan 2018 and Dec 2024, across 376 billing codes. Its largest line is 99283, emergency room visit (moderate) — 32% of everything it billed.
33Billing provider infoCHILDREN'S HOSPITAL COLORADO
AURORA, CO 80045
AURORA, CO 80045
33aNPI1336245828assigned 09/15/2006
33bProvider typeDevelopmentally Disabled Services Day Training Agency
28Total paid$114.90M
24GClaims1,144,502
24DCodes billed376
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Developmentally Disabled Services Day Training Agency providers in Colorado
Rank by total paid#1 of 152
Median peer was paid$2.44M
This provider vs. median47×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MICHAEL, LINDA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 292,963 | $25.74M | |
| 2019 | 238,248 | $22.90M | |
| 2020 | 153,229 | $15.07M | |
| 2021 | 139,830 | $14.50M | |
| 2022 | 116,523 | $14.16M | |
| 2023 | 109,526 | $12.29M | |
| 2024incomplete | 94,183 | $10.24M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 32% | 124,387 | 117,343 | $37.34M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 9.3% | 41,456 | 39,158 | $10.67M |
| 41899 | Unlisted procedure, dentoalveolar structures | 5.4% | 2,628 | 2,409 | $6.22M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 4.1% | 3,401 | 3,044 | $4.70M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 4.0% | 23,456 | 8,431 | $4.63M |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | 3.8% | 26,263 | 24,867 | $4.31M |
| 95782 | 2.2% | 1,663 | 1,575 | $2.51M | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | 2.2% | 15,399 | 14,664 | $2.47M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.0% | 42,956 | 18,182 | $2.28M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.9% | 8,599 | 8,283 | $2.15M |
| 97803 | 1.9% | 12,307 | 11,261 | $2.14M | |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 1.7% | 6,175 | 5,798 | $1.94M |
364 more codes
| 92012 | Ophthalmological services: medical examination and evaluation, intermediate, established patient | 1.4% | 10,952 | $1.57M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.2% | 34,122 | $1.41M |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | 1.2% | 9,403 | $1.41M |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | 1.1% | 2,922 | $1.30M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.0% | 10,483 | $1.15M |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 27,230 | $972K |
| J0475 | Injection, baclofen, 10 mg | <1% | 1,000 | $971K |
| 92609 | <1% | 5,264 | $969K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,624 | $912K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 23,456 | $865K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 5,526 | $783K |
| 92508 | Group treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 7,497 | $768K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,209 | $700K |
| 76770 | <1% | 2,413 | $683K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 2,354 | $668K |
| 93325 | <1% | 4,723 | $649K | |
| 96125 | <1% | 860 | $635K | |
| 96118 | <1% | 709 | $577K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 9,547 | $549K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 3,574 | $540K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 192,039 | $491K |
| G0378 | Hospital observation service, per hour | <1% | 848 | $447K |
| 97802 | <1% | 1,720 | $428K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 29,512 | $422K |
| 92523 | <1% | 1,753 | $420K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 9,547 | $405K |
| 94010 | <1% | 3,990 | $386K | |
| 80053 | Comprehensive metabolic panel | <1% | 9,786 | $382K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 4,160 | $360K |
| 81025 | <1% | 4,454 | $358K | |
| 97161 | <1% | 5,108 | $343K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 6,285 | $318K |
| 11900 | <1% | 609 | $292K | |
| 92526 | <1% | 1,778 | $292K | |
| 74018 | <1% | 3,310 | $288K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 6,556 | $286K |
| 36415 | Collection of venous blood by venipuncture | <1% | 31,372 | $283K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 10,854 | $270K |
| 97760 | <1% | 5,727 | $263K | |
| 51798 | <1% | 1,764 | $263K | |
| 80197 | <1% | 2,923 | $245K | |
| 96132 | <1% | 270 | $232K | |
| 92587 | <1% | 1,162 | $217K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 81 | $212K |
| 94060 | <1% | 1,290 | $180K | |
| 97165 | <1% | 1,452 | $179K | |
| 95816 | <1% | 490 | $175K | |
| 99173 | <1% | 1,920 | $158K | |
| 81001 | <1% | 2,611 | $156K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 15,657 | $152K |
| 92551 | <1% | 3,335 | $152K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,397 | $150K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 112 | $145K |
| 97166 | <1% | 1,637 | $143K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,512 | $141K |
| 92610 | <1% | 798 | $140K | |
| 93225 | <1% | 1,485 | $136K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 52 | $134K |
| 90686 | <1% | 2,905 | $130K | |
| 99499 | <1% | 251 | $125K | |
| 72082 | <1% | 912 | $123K | |
| J3490 | Unclassified drugs | <1% | 21,335 | $122K |
| 96116 | <1% | 189 | $118K | |
| 82728 | <1% | 6,267 | $116K | |
| 95012 | <1% | 1,552 | $115K | |
| D9223 | Deep sedation/general anesthesia - each subsequent 15 minute increment | <1% | 150 | $113K |
| 97162 | <1% | 1,850 | $112K | |
| 80069 | <1% | 3,141 | $112K | |
| 84510 | <1% | 1,915 | $112K | |
| 95811 | <1% | 72 | $111K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 160 | $107K |
| 91300 | <1% | 7,308 | $103K | |
| 0002A | <1% | 4,177 | $102K | |
| 93226 | <1% | 1,485 | $92K | |
| 96156 | <1% | 531 | $90K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 5,286 | $90K |
| 90378 | <1% | 87 | $89K | |
| 96040 | <1% | 1,679 | $88K | |
| H0035 | Mental health partial hospitalization, treatment, less than 24 hours | <1% | 194 | $87K |
| 96000 | <1% | 197 | $83K | |
| 93320 | <1% | 3,055 | $79K | |
| 51736 | <1% | 888 | $79K | |
| 80076 | <1% | 1,691 | $79K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 3,345 | $78K |
| 0001A | <1% | 3,131 | $76K | |
| 96133 | <1% | 345 | $71K | |
| 80061 | Lipid panel | <1% | 2,047 | $66K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 58,557 | $64K |
| 87631 | <1% | 445 | $59K | |
| 70360 | <1% | 373 | $59K | |
| 83735 | <1% | 2,519 | $56K | |
| 62370 | <1% | 268 | $50K | |
| 85046 | <1% | 5,950 | $49K | |
| 84030 | <1% | 1,917 | $48K | |
| 94621 | <1% | 145 | $44K | |
| 54161 | <1% | 14 | $44K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 14,192 | $43K |
| 17110 | <1% | 199 | $42K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,229 | $41K |
| 73140 | <1% | 443 | $39K | |
| 92585 | <1% | 88 | $39K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 169 | $39K |
| 95819 | <1% | 117 | $38K | |
| 90837 | Psychotherapy session, about an hour | <1% | 290 | $37K |
| 31575 | <1% | 81 | $36K | |
| 93296 | <1% | 481 | $35K | |
| 36430 | <1% | 165 | $34K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,157 | $32K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,935 | $31K |
| 31622 | <1% | 15 | $31K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 106 | $30K |
| 91200 | <1% | 106 | $30K | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 6,829 | $30K |
| 72081 | <1% | 182 | $29K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,705 | $28K |
| 99285 | Emergency room visit (most serious) | <1% | 87 | $28K |
| 51741 | <1% | 74 | $27K | |
| J2704 | Injection, propofol, 10 mg | <1% | 11,231 | $27K |
| 29075 | <1% | 146 | $27K | |
| 77072 | <1% | 166 | $27K | |
| 74230 | <1% | 165 | $26K | |
| 96136 | <1% | 192 | $26K | |
| 93271 | <1% | 91 | $25K | |
| 83655 | <1% | 409 | $25K | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 3,347 | $25K |
| 95076 | <1% | 103 | $25K | |
| 82977 | <1% | 3,276 | $23K | |
| 80320 | <1% | 127 | $22K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 193 | $22K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 29 | $20K |
| 0296T | <1% | 251 | $20K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 7,778 | $20K |
| 96158 | <1% | 339 | $20K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 25 | $19K |
| 82610 | <1% | 639 | $19K | |
| 87799 | <1% | 502 | $19K | |
| 83970 | <1% | 564 | $18K | |
| 90474 | <1% | 869 | $18K | |
| 96137 | <1% | 162 | $17K | |
| 95079 | <1% | 85 | $17K | |
| 72170 | <1% | 197 | $17K | |
| 84436 | <1% | 1,286 | $17K | |
| 86140 | <1% | 983 | $16K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 361 | $15K |
| 95715 | <1% | 12 | $15K | |
| 0297T | <1% | 251 | $15K | |
| 97164 | <1% | 310 | $14K | |
| 82784 | <1% | 841 | $14K | |
| 82570 | <1% | 850 | $14K | |
| 97763 | <1% | 337 | $14K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 100 | $14K |
| 99201 | <1% | 13,822 | $13K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 156 | $13K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,324 | $13K |
| 83516 | <1% | 852 | $13K | |
| 92524 | <1% | 139 | $13K | |
| 91307 | <1% | 784 | $12K | |
| 86850 | <1% | 442 | $12K | |
| 92567 | <1% | 1,828 | $12K | |
| 95991 | <1% | 204 | $11K | |
| 87536 | <1% | 98 | $11K | |
| 96409 | <1% | 55 | $11K | |
| 85027 | <1% | 587 | $11K | |
| 64642 | <1% | 55 | $10K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 111 | $10K |
| 0071A | <1% | 420 | $10K | |
| 96167 | <1% | 1,484 | $10K | |
| 97799 | <1% | 879 | $9K | |
| 77073 | <1% | 77 | $9K | |
| 92579 | <1% | 342 | $9K | |
| 73521 | <1% | 70 | $9K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 358 | $9K |
| 73130 | <1% | 98 | $9K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 1,354 | $9K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,065 | $9K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 2,571 | $8K |
| 96119 | <1% | 30 | $8K | |
| 0072A | <1% | 336 | $8K | |
| 87497 | <1% | 210 | $8K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 154 | $8K |
| 85652 | <1% | 1,150 | $8K | |
| 92522 | <1% | 43 | $7K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 81 | $7K |
| 96152 | <1% | 44 | $7K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 176 | $6K |
| 62322 | <1% | 39 | $6K | |
| 90656 | <1% | 214 | $6K | |
| 20560 | <1% | 356 | $6K | |
| 93246 | <1% | 49 | $6K | |
| 81003 | <1% | 1,063 | $6K | |
| 86364 | <1% | 333 | $6K | |
| 96900 | <1% | 45 | $6K | |
| 87070 | <1% | 421 | $6K | |
| 87808 | <1% | 142 | $6K | |
| 86832 | <1% | 160 | $6K | |
| 73110 | <1% | 68 | $5K | |
| 92557 | <1% | 154 | $5K | |
| 86901 | <1% | 457 | $5K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,198 | $5K |
| 86900 | <1% | 458 | $5K | |
| 95951 | <1% | 13 | $5K | |
| 93247 | <1% | 49 | $5K | |
| 90715 | <1% | 28 | $5K | |
| 83540 | <1% | 558 | $5K | |
| 95700 | <1% | 12 | $4K | |
| 73100 | <1% | 30 | $4K | |
| 73560 | <1% | 35 | $4K | |
| V5020 | Conformity evaluation | <1% | 186 | $4K |
| 93270 | <1% | 42 | $4K | |
| 87081 | <1% | 522 | $4K | |
| 86592 | <1% | 282 | $4K | |
| 82248 | <1% | 179 | $4K | |
| 83550 | <1% | 555 | $4K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 944 | $4K |
| 73090 | <1% | 28 | $4K | |
| 84100 | <1% | 827 | $4K | |
| 31526 | <1% | 19 | $4K | |
| 96154 | <1% | 678 | $4K | |
| 84478 | <1% | 573 | $4K | |
| 83020 | <1% | 107 | $3K | |
| 93243 | <1% | 17 | $3K | |
| 85018 | <1% | 260 | $3K | |
| 86833 | <1% | 160 | $3K | |
| 84460 | <1% | 840 | $3K | |
| 43762 | <1% | 12 | $3K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 121 | $3K |
| 84403 | <1% | 94 | $3K | |
| 64615 | <1% | 15 | $3K | |
| 76825 | <1% | 29 | $3K | |
| 92555 | <1% | 168 | $3K | |
| 93242 | <1% | 17 | $3K | |
| 97750 | <1% | 68 | $3K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 27 | $3K |
| 73564 | <1% | 17 | $3K | |
| 87205 | <1% | 77 | $3K | |
| 92552 | <1% | 122 | $3K | |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 25 | $3K |
| 84305 | <1% | 296 | $3K | |
| 93356 | <1% | 150 | $3K | |
| 84270 | <1% | 41 | $3K | |
| 82785 | <1% | 90 | $3K | |
| 86003 | <1% | 77 | $3K | |
| 97116 | <1% | 85 | $3K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 36 | $3K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 572 | $2K |
| 90480 | <1% | 93 | $2K | |
| 96138 | <1% | 14 | $2K | |
| 76885 | <1% | 12 | $2K | |
| 92060 | <1% | 255 | $2K | |
| 84156 | <1% | 300 | $2K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 21 | $2K |
| 92595 | <1% | 56 | $2K | |
| 92652 | <1% | 40 | $2K | |
| 92015 | Determination of refractive state | <1% | 594 | $2K |
| 84439 | <1% | 391 | $2K | |
| 87899 | <1% | 76 | $2K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 201 | $2K |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 15 | $2K |
| 91320 | <1% | 49 | $2K | |
| 0003A | <1% | 87 | $2K | |
| 96150 | <1% | 13 | $2K | |
| 82652 | <1% | 38 | $2K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 16 | $2K |
| 83520 | <1% | 136 | $2K | |
| 76827 | <1% | 29 | $2K | |
| 87486 | <1% | 27 | $2K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 431 | $2K |
| 87503 | <1% | 36 | $2K | |
| 86762 | <1% | 27 | $2K | |
| 81321 | <1% | 24 | $2K | |
| 92611 | <1% | 401 | $1K | |
| 81302 | <1% | 12 | $1K | |
| 83993 | <1% | 16 | $1K | |
| 87077 | <1% | 163 | $1K | |
| 69210 | <1% | 13 | $1K | |
| 92133 | <1% | 24 | $1K | |
| 0124A | <1% | 33 | $1K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,014 | $1K |
| 90911 | <1% | 648 | $1K | |
| 36416 | <1% | 2,282 | $1K | |
| 86923 | <1% | 28 | $1K | |
| D1120 | Dental cleaning, child | <1% | 24 | $1K |
| 98976 | <1% | 27 | $1K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 22 | $1K |
| L3030 | Foot, insert, removable, formed to patient foot, each | <1% | 646 | $1K |
| 85397 | <1% | 14 | $1K | |
| 87181 | <1% | 195 | $1K | |
| 92025 | <1% | 14 | $995.42 | |
| 86255 | <1% | 47 | $973.60 | |
| 87184 | <1% | 194 | $939.23 | |
| 81405 | <1% | 25 | $860.45 | |
| 81407 | <1% | 25 | $860.45 | |
| 76000 | <1% | 14 | $850.40 | |
| 64643 | <1% | 40 | $845.00 | |
| 90912 | <1% | 730 | $842.09 | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 27 | $832.78 |
| 96155 | <1% | 163 | $812.80 | |
| 81406 | <1% | 25 | $798.98 | |
| 85610 | <1% | 80 | $796.74 | |
| 84402 | <1% | 41 | $795.24 | |
| D1206 | Topical application of fluoride varnish | <1% | 24 | $792.00 |
| 81408 | <1% | 25 | $768.25 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 27 | $749.32 |
| 87581 | <1% | 27 | $749.32 | |
| 81404 | <1% | 24 | $737.52 | |
| 92591 | <1% | 14 | $717.53 | |
| 82542 | <1% | 12 | $700.37 | |
| V5011 | Fitting/orientation/checking of hearing aid | <1% | 35 | $633.28 |
| 80047 | <1% | 13 | $608.92 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 42 | $607.32 |
| 86376 | <1% | 113 | $605.48 | |
| 92582 | <1% | 227 | $604.27 | |
| 91312 | <1% | 33 | $576.53 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 221 | $551.70 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 47 | $525.64 |
| D0120 | Dental checkup, returning patient | <1% | 15 | $510.00 |
| 87071 | <1% | 15 | $505.68 | |
| 85014 | <1% | 43 | $495.00 | |
| 87340 | <1% | 28 | $493.86 | |
| 86902 | <1% | 92 | $479.79 | |
| 82272 | <1% | 105 | $469.79 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 44 | $461.64 |
| 96002 | <1% | 123 | $448.04 | |
| 92556 | <1% | 91 | $409.75 | |
| 82950 | <1% | 51 | $371.13 | |
| 83615 | <1% | 55 | $333.79 | |
| J9370 | Vincristine sulfate, 1 mg | <1% | 102 | $282.55 |
| 96168 | <1% | 255 | $246.47 | |
| 85240 | <1% | 14 | $237.75 | |
| 86920 | <1% | 94 | $231.54 | |
| 90913 | <1% | 401 | $221.60 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 242 | $196.80 |
| 89051 | <1% | 15 | $194.04 | |
| 86677 | <1% | 14 | $169.84 | |
| 84450 | <1% | 48 | $135.98 | |
| J3535 | Drug administered through a metered dose inhaler | <1% | 116 | $135.11 |
| 86800 | <1% | 66 | $127.94 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 13 | $112.65 |
| 82340 | <1% | 32 | $104.98 | |
| 96164 | <1% | 70 | $97.37 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 13 | $89.94 |
| 88108 | <1% | 27 | $86.38 | |
| 36591 | <1% | 29 | $84.02 | |
| 82043 | <1% | 61 | $76.64 | |
| V5266 | Battery for use in hearing device | <1% | 393 | $65.70 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 143 | $51.68 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 58 | $46.38 |
| 82947 | <1% | 14 | $43.50 | |
| A4364 | Adhesive, liquid or equal, any type, per oz | <1% | 56 | $39.56 |
| 96165 | <1% | 51 | $26.95 | |
| 82803 | <1% | 26 | $25.40 | |
| A4627 | Spacer, bag or reservoir, with or without mask, for use with metered dose inhaler | <1% | 188 | $6.75 |
| 96159 | 0% | 219 | $0.00 | |
| V5257 | Hearing aid, digital, monaural, bte | 0% | 153 | $0.00 |
| L1832 | Knee orthosis, adjustable knee joints (unicentric or polycentric), positional orthosis, rigid support, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise | 0% | 28 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 14 | $0.00 |
| C1769 | Guide wire | 0% | 14 | $0.00 |
| V5264 | Ear mold/insert, not disposable, any type | 0% | 154 | $0.00 |
| 96171 | 0% | 14 | $0.00 | |
| 86803 | 0% | 12 | $0.00 | |
| 96170 | 0% | 29 | $0.00 | |
| 96139 | 0% | 14 | $0.00 | |
| 96151 | 0% | 28 | $0.00 | |
| J9250 | Methotrexate sodium, 5 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMICHAEL, LINDA (VP, CHIEF COMPLIANCE OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.